Global and China Triptolide Market Size Forecast and In-Depth Research Report on Prospects, 2025–2031

4.3.1 Sales Volume of Key Chinese Triptolide Manufacturers (2020–2025) 4.3.2 Revenue of Key Chinese Triptolide Manufacturers (2020–2025) 4.3.3 Ranking of Top Chinese Triptolide Producers by Revenue in 2024 4.3.4 Sales Prices of Triptolide Offered by Key Chinese Manufacturers (2020–2025) 4.4 Global Key Triptolide Manufacturers: Headquarters and Production Site Distribution 4.5 Establishment Years and Commercialization Dates of Triptolide Products for Global Key Manufacturers 4.6 Product Types and Applications of Triptolide Offered by Global Key Manufacturers 4.7 Industry Concentration and Competitive Landscape Analysis 4.7.1 Industry Concentration Analysis: Market Share of the Global Top 5 Producers in 2024 4.7.2 First-Tier, Second-Tier, and Third-Tier Global Triptolide Producers (Brands) and Their Respective Market Shares 4.8 New Investments and M&A Activities 5 Analysis of Global Key Manufacturers 5.1 Tokyo Chemical Industry 5.1.1 Tokyo Chemical Industry: Basic Information, Triptolide Production Bases, Sales Regions, Competitors, and Market Position 5.1.2 Tokyo Chemical Industry’s Triptolide Product Specifications, Parameters, and Market Applications 5.1.3 Tokyo Chemical Industry’s Triptolide Sales Volume, Revenue, Pricing, and Gross Margin (2020–2025) 5.1.4 Company Profile and Core Business of Tokyo Chemical Industry 5.1.5 Latest Corporate Developments of Tokyo Chemical Industry 5.2 SenesTech 5.2.1 SenesTech: Basic Information, Triptolide Production Bases, Sales Regions, Competitors, and Market Position 5.2.2 SenesTech’s Triptolide Product Specifications, Parameters, and Market Applications 5.2.3 SenesTech’s Triptolide Sales Volume, Revenue, Pricing, and Gross Margin (2020–2025) 5.2.4 Company Profile and Core Business of SenesTech 5.2.5 Latest Corporate Developments of SenesTech 5.3 Nacalai Tesque 5.3.1 Nacalai Tesque: Basic Information, Triptolide Production Bases, Sales Regions, Competitors, and Market Position 5.3.2 Nacalai Tesque’s Triptolide Product Specifications, Parameters, and Market Applications 5.3.3 Nacalai Tesque’s Triptolide Sales Volume, Revenue, Pricing, and Gross Margin (2020–2025) 5.3.4 Company Profile and Core Business of Nacalai Tesque 5.3.5 Latest Corporate Developments of Nacalai Tesque

U.S. Stock Tracking — May 15, 2020

May 21: Opened down -5.28%, rebounded to close at -0.86%; touched a low once; closed -2.78% above the opening price; turnover rate: 1.64%; market capitalization below enterprise value; held by 14 institutions (23.58% of shares); no analyst recommendations; worth monitoring, but trading volume is too low—exercise caution. IBIO (iBio, Inc.) A biotechnology company headquartered in New York, providing product development and manufacturing services to clients, collaborators, and third parties in the U.S. and internationally. Its services span preclinical development, regulatory approval, commercial product launch, and ongoing commercial-stage requirements. Its lead therapeutic candidate is IBIO-CFB03, intended for systemic sclerosis, idiopathic pulmonary fibrosis, and other fibrotic diseases. It also develops candidate vaccines for third parties and offers a suite of product and process development, analytical, and manufacturing services. The company holds a licensing agreement with the University of Natural Resources and Life Sciences, Vienna; has established a strategic partnership with Beijing CC-Pharming Ltd.; and maintains collaboration agreements with AzarGen Biotechnologies (Pty) Ltd., Texas A&M University System, and the Fraunhofer Institute for Molecular Biology and Applied Ecology. Total revenue quadrupled in 2019 but declined by one-third over the trailing twelve months; net income remains unrealized; cash balance dropped to one-quarter of the prior year’s level in 2019; deferred revenue increased tenfold. The stock hit a low of $0.05 on November 19, 2019, and peaked at $3.40 on February 28, 2020. May 21: Opened down -3.26%, rebounded to +10.14%; experienced multiple intraday lows and highs; closed +5.07% above the opening price; turnover rate: 9.86%; market capitalization above enterprise value; held by 24 institutions (12.67% of shares); no analyst recommendations; buying at highs carries risk. SNES (SenesTech, Inc.) Develops technologies for managing animal pest populations via fertility control; founded in 2004 and headquartered in Phoenix, Arizona. The company offers ContraPest—a fertility-targeting liquid bait that suppresses reproductive capacity in both male and female rats to control populations—and is developing a portfolio of fertility-control and animal health products, including wildlife fertility control, non-surgical abortion and sterilization, boar taint mitigation, and cancer treatments for animals. Total revenue fluctuated sharply; declined by half in 2019 versus the prior year; net income remains unrealized; cash balance fell by 60%. The stock peaked at $13.00 on January 6, 2020, and hit a low of $1.32 on May 18, 2020. May 21: Opened up +1.59%, traded with volatility—declined, rallied, declined again to -4.45%, then underwent repeated intraday rallies and pullbacks—closed -1.27% below the opening price; turnover rate: 7.39%; market capitalization above enterprise value; held by 26 institutions (21.78% of shares); two analysts recommended buying; highest-risk scenario; extremely low trading volume—unsuitable for trading.

SenesTech Shifts to Rodent Birth Control: What It Means for SenesTech Stock

1 day ago

SenesTech Inc pivoted its strategy to focus on rodent birth control, achieving $770,000 Q2 2026 revenue with a 76.6% gross margin while targeting e-commerce growth to offset losses.

ad-hoc-news.de

2026-05-07

SenesTech Appoints Michael Edell as President and Chief Executive Officer to Drive Revenue Growth and Scalable Sales Channels

2026-05-07

SenesTech Names Michael Edell as President and CEO

2026-05-07

SenesTech Appoints Michael Edell as CEO with 5% Equity Option Grant

2026-05-12

SenesTech Reports Record Direct-to-Consumer and Subscription Growth Following Strategic E-Commerce Transition

2026-05-12

SenesTech Reports Q1 Revenue Up 2%, Appoints New CEO